| Similar Articles |
|---|
 |
The Motley Fool
December 4, 2007
Brian Lawler |
Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash.   |
The Motley Fool
April 5, 2011
Frank Vinluan |
Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat. |
The Motley Fool
November 11, 2005
Stephen D. Simpson |
Axcan Not in the Ash Can The base business of this Canadian specialty pharmaceutical won't grow quickly, but cash flow and the potential of the new ITAX drug could still move the shares. |
The Motley Fool
August 14, 2007
Billy Fisher |
A Surging Small Cap in Canada Drugmaker Axcan reports a record third-quarter. Investors, this stock has soared more than 42% over the past 52 weeks. |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Axcan's Got Guts While growth for this Canadian drug company is a bit sluggish, ITAX could be a major winner. Investors looking at Axcan shares should treat this stock like a hybrid biotech stock. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
February 22, 2006
Stephen D. Simpson |
Axcan Kicked in the Guts The failure of a phase 3 trial puts future growth prospects for Canadian specialty pharmaceutical AxcanPharma in doubt. Investors, take note. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
Pharmaceutical Executive
January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
